New PET scans aim to spot prostate cancer more clearly

NCT ID NCT07365397

Not yet recruiting Diagnosis Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests three new radioactive imaging agents against a standard one for PET/CT scans in 9 men with advanced prostate cancer. The goal is to see which agent best highlights cancer lesions in the body. It is an early-stage imaging study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-labeled PSMA probes (imaging agents)
What this could lead to: If successful, this could identify better imaging agents for detecting prostate cancer spread.
What could go wrong: This is a very small, early-phase study with only 9 participants, so results may not apply broadly. It focuses on imaging, not treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.